Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CARDIOQUIN vs CARDRASE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Class IA antiarrhythmic agent; blocks sodium channels, slows phase 0 depolarization, prolongs action potential duration, and increases effective refractory period. Also exhibits anticholinergic and negative inotropic effects.
CARDRASE is a nonsteroidal anti-inflammatory drug that inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), thereby reducing the synthesis of prostaglandins involved in inflammation, pain, and fever.
Conversion and prevention of atrial fibrillation/flutter,Suppression of ventricular arrhythmias,Maintenance of sinus rhythm after cardioversion
Rheumatoid arthritis,Osteoarthritis,Ankylosing spondylitis,Acute gouty arthritis,Primary dysmenorrhea
Quinidine gluconate extended-release: 324-648 mg orally every 8-12 hours. Quinidine sulfate immediate-release: 200-400 mg orally every 6 hours. Quinidine sulfate extended-release: 300-600 mg orally every 8-12 hours. Maximum dose: 3-4 g/day.
Adult: 100 mg orally twice daily.
Terminal elimination half-life: 6-8 hours in patients with normal renal function. Prolonged in renal impairment (up to 16-40 hours) and heart failure, requiring dose adjustment.
Terminal elimination half-life is 12-15 hours in adults with normal renal function; prolonged to 24-40 hours in severe renal impairment (Cr Cl <30 m L/min).
Primarily hepatic via CYP3A4; also metabolized by CYP2D6 to active metabolite (3-hydroxyquinidine).
Hepatic metabolism primarily via CYP2C9, with minor contributions from CYP3A4 and CYP2C8. Metabolites are inactive and excreted renally.
Renal: 60-80% as unchanged drug and metabolites (primarily hydroxylated metabolites). Biliary/fecal: 20-40%.
Primarily renal excretion of unchanged drug (60-70%) and glucuronide conjugate (10-20%); biliary/fecal elimination accounts for 10-15%.
80-90% bound, primarily to alpha-1-acid glycoprotein (AAG) and albumin.
98% bound primarily to albumin; minor binding to alpha-1-acid glycoprotein.
Vd: 2-3 L/kg. Large Vd indicates extensive tissue distribution, with high affinity for myocardial tissue.
0.2-0.3 L/kg, indicating limited distribution into tissues, consistent with high plasma protein binding.
Oral: 70-85% (may be reduced in heart failure). Intravenous: 100%.
Oral bioavailability is 80-90% with modest first-pass metabolism; intravenous administration yields 100% bioavailability.
Cr Cl 30-50 m L/min: administer 75% of normal dose every 8-12 hours. Cr Cl 10-29 m L/min: administer 50% of normal dose every 8-12 hours. Cr Cl <10 m L/min: administer 30% of normal dose every 8-12 hours. Hemodialysis: administer after dialysis on dialysis days.
GFR ≥60 m L/min: No adjustment. GFR 30-59 m L/min: 100 mg once daily. GFR 15-29 m L/min: 50 mg once daily. GFR <15 m L/min: Not recommended.
Child-Pugh Class A: no adjustment necessary. Child-Pugh Class B: reduce dose by 25% and monitor QT interval. Child-Pugh Class C: reduce dose by 50% and monitor QT interval closely.
Child-Pugh A: No adjustment. Child-Pugh B: 50 mg once daily. Child-Pugh C: Not recommended.
For supraventricular tachyarrhythmias: Quinidine sulfate 15-60 mg/kg/day orally divided every 6 hours; Quinidine gluconate 15-60 mg/kg/day orally divided every 8-12 hours. Maximum single dose: 400 mg. Maximum daily dose: 3 g.
Children ≥1 year: 2 mg/kg orally twice daily, up to a maximum of 100 mg/dose.
Initiate at lower doses (e.g., quinidine sulfate 200 mg orally every 8-12 hours) and titrate slowly due to decreased renal function and increased risk of QT prolongation and cinchonism. Monitor serum creatinine, QT interval, and quinidine levels. Adjust dose based on renal function.
Initial dose of 50 mg once daily; may increase to 100 mg once daily based on tolerability.
May cause fatal arrhythmias (e.g., torsade de pointes, ventricular fibrillation) especially in patients with structural heart disease, hypokalemia, or bradycardia.
Increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. Risk increases with duration of use and in patients with cardiovascular risk factors. Contraindicated for treatment of perioperative pain in coronary artery bypass graft surgery.
Risk of proarrhythmia; monitor ECG, electrolytes, hepatic/renal function; avoid in QT prolongation; may cause cinchonism (tinnitus, hearing loss, visual disturbances); caution in myasthenia gravis, heart failure, and hepatic impairment.
Cardiovascular risk, gastrointestinal bleeding, renal toxicity, hypertension, fluid retention, anaphylactoid reactions, serious skin reactions, hematologic toxicity, hepatic impairment, asthma exacerbation, and use in pregnancy (avoid in later stages).
Complete AV block without pacemaker,Long QT syndrome,Myasthenia gravis,Hypersensitivity to quinine/quinidine,Cardiogenic shock,Digitalis toxicity
Hypersensitivity to CARDRASE or any NSAID; history of asthma, urticaria, or allergic-type reactions after aspirin or NSAIDs; perioperative pain in CABG surgery; advanced renal disease; severe hepatic impairment; active peptic ulcer or GI bleeding; third trimester of pregnancy; patients with known sulfonamide allergy (if applicable).
Avoid grapefruit and grapefruit juice; they inhibit CYP3A4 metabolism, increasing quinidine levels. Take with food to reduce gastrointestinal upset, but avoid high-potassium foods (e.g., bananas, oranges, spinach) if potassium levels are low.
Avoid high-sodium foods to reduce fluid retention. Limit intake of potassium-rich foods if hyperkalemia is a risk. Grapefruit juice may increase drug levels; avoid concurrent use.
Quinidine, the active ingredient in CARDIOQUIN, is classified as FDA Pregnancy Category C. First trimester: Limited data, but animal studies have shown teratogenic effects at high doses. Second and third trimesters: No adequate well-controlled studies; potential risk of fetal tachycardia, thrombocytopenia, and neonatal coagulopathy. Use only if potential benefit outweighs risk.
First trimester: Potential for increased risk of major malformations based on animal studies; human data insufficient. Second trimester: No specific fetal risks identified. Third trimester: Risk of neonatal hypoglycemia, hypotonia, and respiratory depression with maternal use near term.
Quinidine is excreted into breast milk with a milk-to-plasma ratio of approximately 0.7-0.9. Limited data suggest low risk to nursing infant, but monitor for arrhythmias, cinchonism, and thrombocytopenia. Use with caution.
Limited data; drug is excreted in breast milk. M/P ratio unknown. Avoid breastfeeding during therapy due to potential adverse effects in the infant.
Increased volume of distribution and renal clearance in pregnancy may require dose adjustments. Monitor serum quinidine levels and titrate to therapeutic effect. Lower starting doses may be needed due to altered protein binding.
Increased renal clearance during pregnancy may require 20-30% dose escalation in second and third trimesters. Monitor therapeutic drug levels to maintain efficacy. Consider dose reduction postpartum.
Cardioquin (quinidine) is a class Ia antiarrhythmic. Monitor QRS and QT intervals; risk of torsades de pointes, especially with hypokalemia or hypomagnesemia. Coadministration with digoxin requires digoxin dose reduction due to decreased clearance. Avoid in patients with myasthenia gravis, as it can exacerbate weakness. Use with caution in hepatic impairment.
CARDRASE (carbonic anhydrase inhibitor) may cause metabolic acidosis; monitor serum bicarbonate. Contraindicated in cirrhosis due to risk of hepatic encephalopathy. Can cause hypokalemia; check electrolytes. Adjust dose in renal impairment (Cr Cl <30 m L/min).
Take exactly as prescribed; do not skip doses or stop without consulting your doctor.,Report any fainting, rapid heartbeat, or chest pain immediately.,Avoid grapefruit and grapefruit juice; they increase quinidine levels and risk of side effects.,Limit alcohol intake; it may increase side effects like dizziness and drowsiness.,Notify all healthcare providers you are taking quinidine.
Take with food to reduce gastrointestinal upset.,Drink plenty of fluids to prevent kidney stones.,Avoid prolonged sun exposure; use sunscreen as photosensitivity may occur.,Report unexplained bruising or bleeding, as it may indicate thrombocytopenia.,Do not drive or operate machinery until you know how this medication affects you, as dizziness or drowsiness can occur.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CARDIOQUIN vs CARDRASE, answered by our medical review team.
CARDIOQUIN is a Antiarrhythmic Agent that works by Class IA antiarrhythmic agent; blocks sodium channels, slows phase 0 depolarization, prolongs action potential duration, and increases effective refractory period. Also exhibits anticholinergic and negative inotropic effects.. CARDRASE is a Antiarrhythmic Agent that works by CARDRASE is a nonsteroidal anti-inflammatory drug that inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), thereby reducing the synthesis of prostaglandins involved in inflammation, pain, and fever.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CARDIOQUIN and CARDRASE depend on the specific clinical indication. These are both Antiarrhythmic Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CARDIOQUIN is: Quinidine gluconate extended-release: 324-648 mg orally every 8-12 hours. Quinidine sulfate immediate-release: 200-400 mg orally every 6 hours. Quinidine sulfate extended-release: 300-600 mg orally every 8-12 hours. Maximum dose: 3-4 g/day.. The standard adult dose of CARDRASE is: Adult: 100 mg orally twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CARDIOQUIN and CARDRASE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CARDIOQUIN is classified as Category C. Quinidine, the active ingredient in CARDIOQUIN, is classified as FDA Pregnancy Category C. First trimester: Limited data, but animal studies have shown teratogenic effects at high . CARDRASE is classified as Category C. First trimester: Potential for increased risk of major malformations based on animal studies; human data insufficient. Second trimester: No specific fetal risks identified. Third t. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.